# Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.

> **NCT03248427** · PHASE2 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 106 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03248427
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-13
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-07-20
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2021-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03248427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03248427, "Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03248427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*